Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate Cancer.
Pook D, Geynisman DM, Carles J, de Braud F, Joshua AM, Pérez-Gracia JL, Llácer Pérez C, Shin SJ, Fang B, Barve M, Maruzzo M, Bracarda S, Kim M, Kerloeguen Y, Gallo JD, Maund SL, Harris A, Huang KC, Poon V, Sutaria DS, Gurney H. Pook D, et al. Among authors: fang b. Clin Cancer Res. 2023 Sep 1;29(17):3292-3300. doi: 10.1158/1078-0432.CCR-22-2585. Clin Cancer Res. 2023. PMID: 37339186 Clinical Trial.
Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021).
Agarwal N, McGregor B, Maughan BL, Dorff TB, Kelly W, Fang B, McKay RR, Singh P, Pagliaro L, Dreicer R, Srinivas S, Loriot Y, Vaishampayan U, Goel S, Curran D, Panneerselvam A, Schwickart M, Choueiri TK, Pal S. Agarwal N, et al. Among authors: fang b. Lancet Oncol. 2022 Jul;23(7):899-909. doi: 10.1016/S1470-2045(22)00278-9. Epub 2022 Jun 9. Lancet Oncol. 2022. PMID: 35690072 Clinical Trial.
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, Tagawa ST, Nordquist LT, Vaishampayan N, El-Haddad G, Park CH, Beer TM, Armour A, Pérez-Contreras WJ, DeSilvio M, Kpamegan E, Gericke G, Messmann RA, Morris MJ, Krause BJ; VISION Investigators. Sartor O, et al. N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23. N Engl J Med. 2021. PMID: 34161051 Free PMC article. Clinical Trial.
Clinical Value of Timely Targeted Therapy for Patients With Advanced Non-Small Cell Lung Cancer With Actionable Driver Oncogenes.
Stricker T, Jain N, Ma E, Yu E, Wang R, Schuldt R, Price R, Szado T, Sussell J, Ogale S, Lin V, Arrowsmith E, Slater D, Vaena D, Staszewski H, Fang B, Seneviratne L, Daniel D. Stricker T, et al. Among authors: fang b. Oncologist. 2024 Feb 28:oyae022. doi: 10.1093/oncolo/oyae022. Online ahead of print. Oncologist. 2024. PMID: 38417095 Free article.
Results from a Real-World Multicenter Analysis of 482 Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Look at Racial Differences.
Barrientos JC, Ayed AO, Cha A, Du S, Fang B, Hall R, Marks SM, Peng E, Rhodes JM, Ryan K, Winters SB, Yeung PL, Hou JZ. Barrientos JC, et al. Among authors: fang b. Target Oncol. 2023 Sep;18(5):727-734. doi: 10.1007/s11523-023-00988-0. Epub 2023 Sep 20. Target Oncol. 2023. PMID: 37728835 Free PMC article.
Improving biomarker testing in advanced non-small-cell lung cancer and metastatic colorectal cancer: experience from a large community oncology network in the USA.
Schwartzberg L, Daniel D, Vaena D, Slater D, Staszewski H, Fang B, Seneviratne L, Yu E, Price R, Szado T, Meyer CS, Shah A, Ma E. Schwartzberg L, et al. Among authors: fang b. Future Oncol. 2023 Jun;19(20):1397-1414. doi: 10.2217/fon-2022-1216. Epub 2023 Jun 15. Future Oncol. 2023. PMID: 37318757 Free article.
2,322 results